What is EGRIFTA®?
EGRIFTA® is an injectable prescription medicine to reduce the excess in abdominal fat in HIV-infected patients with lipodystrophy. EGRIFTA® contains a growth hormone-releasing factor (GRF).
The impact and safety of EGRIFTA® on cardiovascular health has not been studied.
EGRIFTA® is not indicated for weight loss management.
It is not known whether taking EGRIFTA® helps improve compliance with anti-retroviral medications.
It is not known if EGRIFTA® is safe and effective in children. EGRIFTA® is not recommended to be used in children.
(tesamorelin for injection) for subcutaneous use
Do not use EGRIFTA® if you:
have pituitary gland tumor, pituitary gland surgery or other problems related to your pituitary gland
have active cancer (either newly diagnosed or recurrent) or are receiving
treatment for cancer
are allergic to tesamorelin or any of the ingredients in EGRIFTA® (including mannitol or sterile water)
are pregnant or become pregnant. If you become pregnant, stop using EGRIFTA® and talk with your healthcare provider.
Before using EGRIFTA®, tell your healthcare provider if you:
have or have had cancer
are breastfeeding or plan to breastfeed. It is not known if EGRIFTA® passes into your breast milk. The Centers for Disease Control and Prevention (CDC) recommends that HIV-infected mothers not breastfeed to avoid the risk of passing HIV infection to your baby. Talk with your healthcare provider about the best way to feed your baby if you are taking EGRIFTA®
have kidney or liver problems
have any other medical condition.
Tell your healthcare provider about all the medicines you take, including prescription and non-prescription medicines, vitamins, and herbal supplements. EGRIFTA® may affect the way other medicines work, and other medicines may affect how EGRIFTA® works.
How should I use EGRIFTA®?
Read the detailed "Instructions for Use" that comes with EGRIFTA® before you start using EGRIFTA®. Your healthcare provider will show you how to inject EGRIFTA®.
Use EGRIFTA® exactly as prescribed by your healthcare provider.
Inject EGRIFTA® under the skin (subcutaneously) of your stomach area (abdomen).
Change (rotate) the injection site on your stomach area (abdomen) with each dose. Do not inject EGRIFTA® into scar tissue, bruises or your navel.
Do not share needles or syringes with other people. Sharing of needles can result in the transmission of infectious diseases, such as HIV.
EGRIFTA® may cause serious side effects including:
Serious allergic reaction. Some people taking EGRIFTA® may have an allergic reaction.
Stop using EGRIFTA® and get emergency help right away if you have any of the following symptoms:
- a rash over your body
- swelling of your face or throat
- shortness of breath or trouble breathing
- fast heartbeat
- feeling of faintness or fainting
Swelling (fluid retention). EGRIFTA® can cause swelling in some parts of your body. Call your healthcare provider if you have an increase in joint pain, or pain or numbness in your hands or wrist (carpal tunnel syndrome).
Increase in glucose (blood sugar) intolerance and diabetes. Your healthcare provider will measure your blood sugar periodically.
Injection site reactions. Change (rotate) your injection site to help lower your risk for injection site reactions. Call your healthcare provider for medical advice if you have the following symptoms around the area of the injection site:
The most common side effects of EGRIFTA® include:
These are not all the possible side effects of EGRIFTA®. For more information, ask your healthcare provider or pharmacist.
Tell your healthcare provider if you have any side effect that bothers you or that does not go away.
Call your doctor for medical advice about side effects. To report side effects, contact EMD Serono toll-free at 1-800-283-8088 ext. 5563. You may report side effects to FDA at 1-800-FDA-1088.
This information is not intended to replace discussion with your healthcare provider. For additional information about EGRIFTA®
, please consult the Prescribing Information, Patient Information, and Patient Instructions for Use, or visit www.egrifta.com
is available by prescription only. For additional contact information, please contact the AXIS Center toll-free at 1-877-714-AXIS (2947).
EGRIFTA® is a registered trademark of Theratechnologies Inc.
© 2013 EMD Serono, Inc. All rights reserved.